OWC Pharmaceutical Research stock | Growth outlook for 2026 & price target

OWC Pharmaceutical R...

OTCPK:OWCP

₪ 0,00

₪0,00 (0,00%)

0,00 ₪

₪0,00 (0,00%)

End-of-day quote: 04/10/2026

OWC Pharmaceutical Research Stock Value

The current analyst rating for OTCPK:OWCP is sf_Data Unavailable.

OWC Pharmaceutical Research Company Info

EPS Growth 5Y

0,00%

Market Cap

₪0,00 B

Long-Term Debt

₪0,00 B

Annual earnings

N/A

Dividend

₪0,00

Dividend Yield

0,00%

Founded

2008

Industry

Health Care

Country

Israel

Website

OWC Pharmaceutical Research

ISIN Number

US67109N1081

Website

http://www.owcpharma.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

There are currently no price targets available for this stock.

In the last five quarters, OWC Pharmaceutical Research’s Price Target has risen from ₪0,00 to ₪0,00 - a 100,00% increase.

Top growth stocks in the health care sector (5Y.)

What does OWC Pharmaceutical Research do?

OWC Pharmaceutical Research Corp., a medical cannabis research and development company, engages in the research and development and has conducted trials on the efficacy of cannabis-based medical products commencing with its cannabis-based topical cream for the treatment of psoriasis. The company is pursuing the use of its Cannabis-Based Medical Products for the treatment of multiple myeloma, post-traumatic stress disorder, chronic pain and fibromyalgia, and has made significant advancements in...

The company is pursuing the use of its Cannabis-Based Medical Products for the treatment of multiple myeloma, post-traumatic stress disorder, chronic pain and fibromyalgia, and has made significant advancements in the development of a cannabis soluble tablet delivery system that could have applications for other indications. The company is capable of providing consulting and advisory services to governmental and private entities to assist them with developing and implementing tailor-made, comprehensive medical cannabis programs.

Research and Development Activities

The company’s research and development activities primarily focuses on exploring various formulations containing active compounds from the cannabis plant, including the cannabinoids cannabidiol and cannabinoids tetrahydrocannabinol, and identifying potential therapeutic applications of based on the synergistic effects of these active compounds. The company is developing delivery systems for its pharmaceutical grade products.

The company acquires the cannabis needed for its research activities from G.K. Medical Cannabis Ltd, Canndoc Ltd, Seach Ltd or IMC Medical Cannabis Ltd, all government-licensed Israeli medical cannabis growers.

Consulting Services

The company’s services are designed to help government officials, policy-makers and regulatory agencies develop and implement tailor-made comprehensive medical cannabis programs. In addition, the company offers medical cannabis regulatory compliance services and patient-care consultancy services.

The company’s initial activities to secure consulting contracts would be in member states of the European Union and states of the United States that allow for public medical cannabis programs in compliance with applicable laws.

Marketing and Sales

The company intends to license to, or enter strategic alliances with, larger companies in the pharmaceutical business, which are equipped to market and/or sell its products, if any, through their marketing capabilities and distribution networks.

Research and Development

During the year ended December 31, 2018, the company spent $712,000 on research and development.

Intellectual Property

As of December 31, 2018, the company’s intellectual property portfolio included 6 patent families and includes 28filings in selected domains at various stages from the Patent Cooperation Treaty filings, National Phase filings and Continuations in Part.

Agreements

The company has a license agreement, Emilia Cosmetics Ltd. granted a limited license to it with respect to Emilia’s licensed intellectual property to be developed and commercialized worldwide in the topical treatment of psoriasis in humans with its and the Emilia Product.

Significant Events

In November 2019, STENOCARE A/S and OWC Pharmaceutical Research Corp. had signed a strategic memorandum of understanding to develop and commercialize new cannabis-based medical products.

History

The company was founded in 2008. It was incorporated in Delaware in 2008. The company was formerly known as Dynamic Applications Corp. and changed its name to OWC Pharmaceutical Research Corp. in 2015.

New support ticket

Explore

OWC Pharmaceutical Research Stock Value

OWC Pharmaceutical Research Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does OWC Pharmaceutical Research do?

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

OWC Pharmaceutical Research Stock Value

OWC Pharmaceutical Research Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does OWC Pharmaceutical Research do?

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.